RxDoctor Payments Data

Kennedy Lim, MD

Internal Medicine · Bossier City, LANPI 1801825211

Payments from drug & device makers

$8,157in general payments, 2019–2025

Across 442 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$849
  • Pfizer$654
  • Novo Nordisk$592
  • Lilly USA, LLC$582
  • Merck$564
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$8,157100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,157 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$248,883
Medicare patients
422
Services billed
2,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide66$68,042
EliquisApixaban61$60,350
JanuviaSitagliptin Phosphate27$29,856
Tresiba Flextouch U-200Insulin Degludec13$22,575
OzempicSemaglutide22$19,703
VascepaIcosapent Ethyl35$19,699
WegovySemaglutide11$16,297
Repatha SureclickEvolocumab13$10,876
EntrestoSacubitril/Valsartan14$10,584
LinzessLinaclotide17$10,035
Icosapent Ethyl13$6,557
Pantoprazole Sodium137$2,013
Montelukast Sodium146$1,869
Gabapentin112$1,808
Ezetimibe-SimvastatinEzetimibe/Simvastatin12$1,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$582$68,04266 claims
PfizerEliquis$654$60,35061 claims
Novo NordiskOzempic, Wegovy$592$35,99933 claims
MerckJanuvia$564$29,85627 claims
AbbVieLinzess, Synthroid$216$11,14844 claims
NovartisEntresto$71$10,58414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →